David A J Wilson1, Aaron Gazendam2, Julia Visgauss3, David Perrin4, Anthony M Griffin4, Peter W Chung5, Charles N Catton5, David Shultz5, Peter C Ferguson4, Jay S Wunder4. 1. Division of Orthopaedic Surgery, Department of Surgery, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada. wilsondaj@gmail.com. 2. Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, ON, Canada. 3. Department of Orthopedic Surgery, Duke University Medical Center, Duke University, Durham, NC, USA. 4. University Musculoskeletal Oncology Unit, Division of Orthopaedic Surgery, Department of Surgery, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada. 5. Princess Margaret Cancer Centre, Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Abstract
PURPOSE: The risk of tumor recurrence after resection of soft tissue sarcoma (STS) necessitates surveillance in follow-up. The objective of this study was to determine the frequency/timing of metastasis and local recurrence following treatment for soft tissue sarcoma, and to use these data to justify an evidence-based follow-up schedule. METHODS: Utilizing a prospective database, a retrospective single center review was performed of all patients with minimum 2-year follow-up after resection of a localized extremity STS. Kaplan-Meier estimates were used to calculate the incidence of local recurrence and metastases on an annual basis for 10 years. RESULTS: We identified a total of 230 low-grade, 626 intermediate-grade and 940 high-grade extremity STS and a total of 721 events, 150 local recurrences and 571 metastases. Based on tumor size and grade, follow-up cohorts were developed that had similar metastatic risk. Using pre-determined thresholds for metastatic event, a follow-up schedule was established for each cohort. CONCLUSION: Based on our results we recommend that patients with small low-grade tumors undergo annual follow-up for 5 years following definitive local treatment. Patients with large low-grade tumors, small intermediate-grade and small high-grade tumors should have follow-up every 6 months for the first 2 years, then yearly to 10 years. Only patients with large intermediate- or high-grade tumors require follow-up every 3 months for the first 2 years, then every 6 months for years 3-5, followed by annually until 10 years.
PURPOSE: The risk of tumor recurrence after resection of soft tissue sarcoma (STS) necessitates surveillance in follow-up. The objective of this study was to determine the frequency/timing of metastasis and local recurrence following treatment for soft tissue sarcoma, and to use these data to justify an evidence-based follow-up schedule. METHODS: Utilizing a prospective database, a retrospective single center review was performed of all patients with minimum 2-year follow-up after resection of a localized extremity STS. Kaplan-Meier estimates were used to calculate the incidence of local recurrence and metastases on an annual basis for 10 years. RESULTS: We identified a total of 230 low-grade, 626 intermediate-grade and 940 high-grade extremity STS and a total of 721 events, 150 local recurrences and 571 metastases. Based on tumor size and grade, follow-up cohorts were developed that had similar metastatic risk. Using pre-determined thresholds for metastatic event, a follow-up schedule was established for each cohort. CONCLUSION: Based on our results we recommend that patients with small low-grade tumors undergo annual follow-up for 5 years following definitive local treatment. Patients with large low-grade tumors, small intermediate-grade and small high-grade tumors should have follow-up every 6 months for the first 2 years, then yearly to 10 years. Only patients with large intermediate- or high-grade tumors require follow-up every 3 months for the first 2 years, then every 6 months for years 3-5, followed by annually until 10 years.
Authors: David J Biau; Peter C Ferguson; Robert E Turcotte; Peter Chung; Marc H Isler; Soha Riad; Anthony M Griffin; Charles N Catton; Brian O'Sullivan; Jay S Wunder Journal: J Clin Oncol Date: 2011-09-19 Impact factor: 44.544
Authors: David J Biau; Peter C Ferguson; Peter Chung; Anthony M Griffin; Charles N Catton; Brian O'Sullivan; Jay S Wunder Journal: Cancer Date: 2012-05-30 Impact factor: 6.860
Authors: Antoine Italiano; Axel Le Cesne; Jean Mendiboure; Jean-Yves Blay; Sophie Piperno-Neumann; Christine Chevreau; Corinne Delcambre; Nicolas Penel; Philippe Terrier; Dominique Ranchere-Vince; Marick Lae; Sophie Le Guellec; Jean-Jacques Michels; Yves Marie Robin; Carine Bellera; Sylvie Bonvalot Journal: Cancer Date: 2014-07-10 Impact factor: 6.860
Authors: Anupam Goel; Matthew E L Christy; Katherine S Virgo; William G Kraybill; Frank E Johnson Journal: Int J Oncol Date: 2004-08 Impact factor: 5.650
Authors: Dario Callegaro; Rosalba Miceli; Sylvie Bonvalot; Peter Ferguson; Dirk C Strauss; Antonin Levy; Anthony Griffin; Andrew J Hayes; Silvia Stacchiotti; Cecile Le Pechoux; Myles J Smith; Marco Fiore; Angelo P Dei Tos; Henry G Smith; Luigi Mariani; Jay S Wunder; Raphael E Pollock; Paolo G Casali; Alessandro Gronchi Journal: Lancet Oncol Date: 2016-04-05 Impact factor: 41.316
Authors: Fritz C Eilber; Gerald Rosen; Scott D Nelson; Michael Selch; Frederick Dorey; Jeffery Eckardt; Frederick R Eilber Journal: Ann Surg Date: 2003-02 Impact factor: 12.969
Authors: Alexander L Lazarides; Harrison R Ferlauto; Zachary D C Burke; Anthony M Griffin; Bruce D Leckey; Nicholas M Bernthal; Jay S Wunder; Peter C Ferguson; Julia D Visgauss; Brian E Brigman; William C Eward Journal: Sarcoma Date: 2021-10-11